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Introduction
Apoptosis related proteins have been involved in
immune dysregulation and development of systemic
lupus erythematosus (SLE).
Objectives
To assess sFas, sFasL, sTRAIL and sBcl-2 in sera and to
evaluate Fas and Bcl-2 expressions in peripheral mono-
cytes, T and B lymphocytes from juvenile-onset SLE
(JSLE) and to determine relationships with disease
activity.
Methods
Forty-three JSLE patients (revised ACR criteria, mean age
= 14.3 yrs, 36F:7M), and 35 age and gender matched
healthy controls were studied; 30 JSLE had SLEDAI score3
4, reflected active disease. Soluble molecules were mea-
sured by commercial ELISA kits. Lymphocytes and mono-
cytes were stained with specific moAbs and analyzed by
flow cytometry. Kruskal-Wallis test and Spearman’s rank
were employed and statistical significance considered
p value < 0.05.
Results
JSLE sera had significantly increased sFas (188.1 ± 69.2
vs 133.2 ± 80.6, pg/ml) and sTRAIL (691.3 ± 631.8 vs
346.6 ± 251.1, pg/ml), decreased sFasL (0.08 ± 0.1 vs
0.36 ± 0.4, ng/ml), and similar sBcl-2 (7.4 ± 8.6 vs 9.3 ±
9.6, mg/ml) levels compared to healthy controls. SLE-
DAI score directly correlated with sFas (r = 0.52; p =
0.001). JSLE patients compared to controls had signifi-
cantly increased Fas expression on CD3+ (43.7 ± 10.3%
vs 28.9 ± 9.4%), CD4+ (20.3 ± 6.7% vs 16.2 ± 6.2%) and
CD8+ (21.5 ± 9.6% vs 12.3 ± 5.8%) T cells, and also on
CD19+ B cells (2.1 ± 1.4% vs 1.4 ± 0.7%), whereas, it
was decreased on CD14+ monocytes (93.6 ± 6.9% vs
96.7 ± 2.5%, p = 0.01). There was direct correlation
between percentages of CD19+Fas+ cells and SLEDAI
(r = 0.38, p = 0.02) and inverse correlation between per-
centages of CD14+Fas+ cells and SLEDAI (r= -0.55, p =
0.01). Mean fluorescence intensity (MFI) of Bcl-2-posi-
tive cells from JSLE patients was significantly increased
in CD3+ (28.8 ± 8.4 vs 22.9 ± 4.2), CD4+ (28.6 ± 8.2 vs
22.9 ± 4.4) and CD8+ (29.4 ± 9.4 vs 22.8 ± 3.6) T cells,
and also in CD19+ B cells (25.5 ± 9.6 vs 21.5 ± 3.6).
Bcl-2 expression in CD14+ monocytes was lower in
JSLE compared to controls (25.2 ± 18.2% vs 34.5 ±
16.6%, p = 0.006). Direct correlation between percen-
tages of CD19+Bcl-2+ cells and SLEDAI (r = 0.47, p =
0.04) was shown.
Conclusion
JSLE patients showing high sFas and sTRAIL and low
sFasL levels with Fas and Bcl-2 expressions increased on
circulating T and B lymphocytes though decreased on
monocytes are remarkable evidences of apoptosis role in
the immune dysregulation observed. A possible role as a
marker for lupus disease activity needs to be defined.
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